Avanos Medical Management
Management criteria checks 3/4
Avanos Medical's CEO is Michael Greiner, appointed in Oct 2024, has a tenure of less than a year. total yearly compensation is $2.99M, comprised of 18.7% salary and 81.3% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €844.53K. The average tenure of the management team and the board of directors is 2.8 years and 10.3 years respectively.
Key information
Michael Greiner
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 18.7% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 2.8yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$22m |
| Jun 30 2024 | n/a | n/a | US$7m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$3m | US$558k | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$11m |
| Jun 30 2023 | n/a | n/a | US$9m |
| Mar 31 2023 | n/a | n/a | US$18m |
| Dec 31 2022 | US$3m | US$514k | US$22m |
| Sep 30 2022 | n/a | n/a | US$23m |
| Jun 30 2022 | n/a | n/a | -US$23m |
| Mar 31 2022 | n/a | n/a | US$10m |
| Dec 31 2021 | US$2m | US$491k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$52m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$3m | US$480k | -US$29m |
Compensation vs Market: Michael's total compensation ($USD2.99M) is above average for companies of similar size in the German market ($USD1.44M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Greiner (51 yo)
less than a year
Tenure
US$2,986,702
Compensation
Mr. Michael C. Greiner has been Senior Vice President of Avanos Medical, Inc. since January 1, 2020 serves as its Chief Transformation Officer since January 10, 2023 and serves as its Interim CEO since Oct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | less than a year | US$2.99m | 0.13% € 844.5k | |
| Senior VP | 3.5yrs | US$1.90m | 0.045% € 291.5k | |
| Senior VP & Chief Commercial Officer | 5.7yrs | US$2.15m | 0.20% € 1.3m | |
| Interim Chief Financial Officer | less than a year | US$911.19k | 0.022% € 141.1k | |
| Principal Accounting Officer & Controller | 2.8yrs | no data | 0.0091% € 59.1k | |
| VP of FP&A and Investor Relations and Treasurer | no data | no data | no data | |
| Senior VP and Chief Ethics & Compliance Officer | 4.3yrs | no data | no data | |
| Vice President of Strategy & Corporate Development | no data | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Global R&D | no data | no data | no data | |
| Senior Vice President of Integrated Supply Chain | less than a year | no data | no data |
2.8yrs
Average Tenure
57yo
Average Age
Experienced Management: 8HH's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 10.3yrs | US$292.54k | 0.13% € 824.5k | |
| Independent Chairman | 10.3yrs | US$390.00k | 0.14% € 899.2k | |
| Independent Director | 1.8yrs | US$245.15k | 0.032% € 208.4k | |
| Independent Director | 10.3yrs | US$289.38k | 0.12% € 755.8k | |
| Independent Director | less than a year | no data | no data |
10.3yrs
Average Tenure
66yo
Average Age
Experienced Board: 8HH's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 12:03 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avanos Medical, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ravi Misra | Berenberg |
| Kristen Stewart | CL King & Associates, Inc. |
| Kristen Stewart | Deutsche Bank |